IOL Chemicals & Pharmaceuticals Ltd Q4 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/xunen93evl4szicrp3zapp4w.pdf

Key Takeaways


Margin Recovery & Profitability

Abhay Raj Singh: "We assume and we consider that anything in the API business around 15% to 17%, 18% is very much sustainable."

Ibuprofen: Volume-Led Growth & Competitive Moat

Rakesh Mahajan: "China is not coming with any new fresh capacity as per our knowledge because they require the Isobutyl Benzene, for which India is the only supplier. They are not able to produce Isobutyl Benzene there."

Paracetamol: Capacity, Approvals & Backward Integration

Rakesh Mahajan: "As of our information, we will be the first company in the world which is backward integrated."

Non-Ibuprofen APIs & Regulatory Pipeline


Specialty Chemicals: Recovery & Europe Entry


Capital Allocation & Balance Sheet


Guidance & Commitments

CommitmentSpecificsTimeline
Revenue growth10-15% from FY23 base, on a conservative basisFY24
Overall EBITDA marginMaintain around 15-16%Ongoing
API segment sustainable EBITDA margin12-15%Ongoing
Chemical segment sustainable EBITDA marginHigher single digitsOngoing
Paracetamol incremental growthDouble digitsFrom Q1 FY24
Paracetamol regulated-market revenueMeaningful contribution after European CEP approval2-3 quarters from May 2023
Acetic anhydride plant commercializationPlant operationalQ1 FY24
Non-Ibuprofen API volume growth~50% growth targetedFY24
CAPEX₹150-200 CrFY24
Receivable daysNormalized at ~80 daysGoing forward
Gross marginMaintain or improve from 35.7%Ongoing
Quarterly performanceMaintain or improvise Q4 performanceComing quarters

Key Metrics

MetricQ4 FY23
Total income₹596 cr, vs ₹579 cr YoY and ₹530 cr QoQ
EBITDA₹104.5 cr, vs ₹50 cr YoY and ₹49.7 cr QoQ
EBITDA margin17.5%, vs 8.6% YoY and 9.4% QoQ
Net profit₹65.3 cr, vs ₹27.7 cr YoY and ₹24.2 cr QoQ
Gross margin35.7%
Pharma segment EBIT margin21.7%, vs 13.5% YoY and 11.5% QoQ
Specialty chemical segment EBIT margin5%, vs -2.2% YoY and -0.5% QoQ
Revenue growth guidance (FY24)10%–15% on a conservative basis
CAPEX target (FY24)₹150 cr to ₹200 cr
CAPEX incurred (FY23)₹220 cr
Ibuprofen capacity utilization85%–90%, up from 60%–70% two to three quarters ago
Non-Ibuprofen volume growth target (FY24)~50%
Exports to regulated markets~40% of total export revenue
Full-year exports (FY23)₹634 cr, vs ₹546 cr in FY22
Receivable days~83 days, normalized level 80 days